AJANTA PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,194 INR | +2.50% |
|
+5.18% | +5.27% |
| 02/02 | Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit | MT |
| 31/01 | Transcript : Ajanta Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024 |
| Sales 2024 * | 42.01B 504M | Sales 2025 * | 47.09B 565M | Capitalization | 276B 3.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.08B 96.91M | Net income 2025 * | 9.5B 114M | EV / Sales 2024 * | 6.39 x |
| Net cash position 2024 * | 7.97B 95.6M | Net cash position 2025 * | 13.8B 166M | EV / Sales 2025 * | 5.57 x |
| P/E ratio 2024 * |
34.6
x | P/E ratio 2025 * |
29.2
x | Employees | 7,713 |
| Yield 2024 * |
0.92% | Yield 2025 * |
0.76% | Free-Float | 50.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ajanta Pharma Limited
| 1 day | +2.50% | ||
| 1 week | +5.18% | ||
| Current month | -1.67% | ||
| 1 month | -1.33% | ||
| 3 months | +0.39% | ||
| 6 months | +28.45% | ||
| Current year | +5.27% |
1 week
2 079.95
2 286.95
1 month
2 051.602 311.95
Current year
1 998.352 353.95
1 year
1 246.752 353.95
3 years
1 061.772 353.95
5 years
550.002 353.95
10 years
259.522 353.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 01/99/01 | |
| Chief Executive Officer | 52 | 01/96/01 | |
| Director of Finance/CFO | 59 | 23/98/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 01/96/01 | |
| Chairman | 77 | 31/79/31 | |
| Director/Board Member | 78 | 20/08/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2,194 | +2.50% | 205,252 |
| 25/24/25 | 2,140 | +0.29% | 35,470 |
| 24/24/24 | 2,134 | +0.16% | 69,788 |
| 23/24/23 | 2,130 | +1.86% | 98,235 |
| 22/24/22 | 2,091 | +0.29% | 138,405 |
Delayed Quote NSE India S.E., April 26, 2024 at 05:13 pm IST
More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
Sector
Pharmaceuticals
Calendar
02/05/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,194
INR
Average target price
2,271
INR
Spread / Average Target
+3.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.27% | 3.31B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- AJANTPHARM Stock
